UY34649A - Compuestos heterobicíclicos - Google Patents

Compuestos heterobicíclicos

Info

Publication number
UY34649A
UY34649A UY0001034649A UY34649A UY34649A UY 34649 A UY34649 A UY 34649A UY 0001034649 A UY0001034649 A UY 0001034649A UY 34649 A UY34649 A UY 34649A UY 34649 A UY34649 A UY 34649A
Authority
UY
Uruguay
Prior art keywords
heterobicyclic compounds
que
del
renglón
pág
Prior art date
Application number
UY0001034649A
Other languages
English (en)
Inventor
Jennifer R Allen
Amegadzie Albert
Kristin L Andrews
Brown James
Jian J Chen
Chen Ning
Harrington Essa Hu
Liu Qingyian
Thomas T Nguyen
Alexander J Pickrell
Qian Wenyuan
Rumfelt Shannon
Robert M Rzasa
Yuan Chester Chenguang
Zhong Wenge
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY34649A publication Critical patent/UY34649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen compuestos heterobicíclicos de Fórmula I, o una sal, tautómero, o estereoisómero farmacéuticamente aceptable del mismo, como se define en la memoria descriptiva, y composiciones que los contienen, y procesos para preparar dichos compuestos. En la presente se proveen también métodos para tratar trastornos o enfermedades que se pueden tratar mediante la inhibición de PDE10, tal como obesidad, diabetes no dependiente de insulina, esquizofrenia, trastorno bipolar, trastorno obsesivo compulsivo, enfermedad de Huntington, y similares.
UY0001034649A 2012-02-29 2013-02-28 Compuestos heterobicíclicos UY34649A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261605148P 2012-02-29 2012-02-29

Publications (1)

Publication Number Publication Date
UY34649A true UY34649A (es) 2013-09-30

Family

ID=47846219

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034649A UY34649A (es) 2012-02-29 2013-02-28 Compuestos heterobicíclicos

Country Status (10)

Country Link
US (1) US9174992B2 (es)
EP (1) EP2820014A1 (es)
JP (1) JP2015508826A (es)
AR (1) AR090203A1 (es)
AU (1) AU2013225838A1 (es)
CA (1) CA2865980A1 (es)
MX (1) MX2014010377A (es)
TW (1) TW201348231A (es)
UY (1) UY34649A (es)
WO (1) WO2013130890A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896871A1 (en) * 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
CN106536518B (zh) * 2014-05-19 2020-05-12 勃林格殷格翰动物保健美国公司 驱蠕虫化合物
WO2016115272A1 (en) 2015-01-13 2016-07-21 Vanderbilt University Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
ES2894301T3 (es) 2015-10-26 2022-02-14 Bayer Cropscience Ag Derivados de heterociclos bicíclicos condensados como pesticidas
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3634964B1 (en) 2017-06-08 2022-02-23 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
EP3704115A1 (en) 2017-11-02 2020-09-09 Calico Life Sciences LLC Modulators of the integrated stress pathway
BR112020008833A2 (pt) * 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
MD3755703T2 (ro) 2018-02-20 2022-10-31 Incyte Corp Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
TW202028207A (zh) 2018-09-25 2020-08-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
WO2020072964A1 (en) 2018-10-05 2020-04-09 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
EP3696175A1 (en) 2019-02-18 2020-08-19 Syngenta Crop Protection AG Pesticidally active azole-amide compounds
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
BR112021017646A2 (pt) 2019-03-08 2021-11-16 Syngenta Crop Protection Ag Compostos de azol-amida ativos em termos pesticidas
ES2972949T3 (es) 2019-03-20 2024-06-17 Syngenta Crop Protection Ag Compuestos de azolamida plaguicidamente activos
EP3941915A1 (en) 2019-03-20 2022-01-26 Syngenta Crop Protection AG Pesticidally active azole amide compounds
CN113597426A (zh) 2019-03-22 2021-11-02 先正达农作物保护股份公司 N-[1-(5-溴-2-嘧啶-2-基-1,2,4-三唑-3-基)乙基]-2-环丙基-6-(三氟甲基)吡啶-4-甲酰胺衍生物及相关的化合物作为杀昆虫剂
TW202102489A (zh) 2019-03-29 2021-01-16 瑞士商先正達農作物保護公司 殺有害生物活性之二𠯤-醯胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
MX2021012290A (es) 2019-04-11 2021-11-12 Syngenta Crop Protection Ag Compuestos de diazina-amida activos como pesticidas.
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
KR20220064369A (ko) 2019-08-14 2022-05-18 인사이트 코포레이션 Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
CA3211159A1 (en) * 2021-02-19 2022-08-25 Kalvista Pharmaceuticals Limited Factor xiia inhibitors
EP4074712A1 (en) 2021-04-13 2022-10-19 Siegfried AG Process for the synthesis of 1,3-dihydro-imidazo[4,5-b]pyridin-2-one and/or derivatives thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2200468A1 (en) * 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
CA2387535A1 (en) * 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SI1598340T1 (sl) * 2001-04-18 2009-08-31 Euro Celtique Sa Derivati 1-(4-piperidinil)-1,3-dihidro-2H-benzoksazol-2-ona in sorodne spojine kot analogi nociceptina in ligandi ORL1 za zdravljenje bolečine
SE0300456D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
JP2008539220A (ja) 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
MX2008010953A (es) 2006-02-28 2008-09-08 Amgen Inc Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用
EP2390254A1 (en) 2009-01-22 2011-11-30 Mitsubishi Tanabe Pharma Corporation NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND
EP2475668A1 (en) 2009-09-10 2012-07-18 Novartis AG Ether derivatives of bicyclic heteroaryls
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
JP5702855B2 (ja) * 2010-05-13 2015-04-15 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤として有用な窒素複素環化合物
WO2011145718A1 (ja) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 新規ピロロ［２，３－ｄ］ピリミジン化合物
JP2012020973A (ja) 2010-07-15 2012-02-02 Mitsubishi Tanabe Pharma Corp 医薬組成物
WO2012022045A1 (en) * 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用

Also Published As

Publication number Publication date
AR090203A1 (es) 2014-10-29
CA2865980A1 (en) 2013-09-06
AU2013225838A1 (en) 2014-09-11
JP2015508826A (ja) 2015-03-23
TW201348231A (zh) 2013-12-01
MX2014010377A (es) 2014-10-23
WO2013130890A1 (en) 2013-09-06
US9174992B2 (en) 2015-11-03
EP2820014A1 (en) 2015-01-07
US20130225552A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
UY34649A (es) Compuestos heterobicíclicos
UY34648A (es) Amidas como inhibidores de pim
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
CL2015003491A1 (es) Compuestos químicos.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA201591420A1 (ru) Гетероарильные соединения и их применение
UY34591A (es) Compuestos de imidazopirrolidinona
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
UY34765A (es) Compuestos novedosos.
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
EA201591137A1 (ru) Ингибиторы mk2 и их применения
UY34559A (es) Inhibidores de bromodominios
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY33925A (es) Inhibidores tricíclicos de quinasas
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201491305A1 (ru) Конденсированные трициклические соединения в качестве ингибиторов raf киназы
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34515A (es) Triazolopiridinas sustituidas
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34817A (es) Tienopirimidinas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210526